Bruce E Johnson

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Phase II study of imatinib in patients with small cell lung cancer
    Bruce E Johnson
    Dana Farber Cancer Institute, Brigham and Women s Hospital and Massachusetts General Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:5880-7. 2003
  2. ncbi request reprint Management of small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Chest Med 23:225-39. 2002
  3. ncbi request reprint Basic treatment considerations using chemotherapy for patients with small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 18:309-22. 2004
  4. ncbi request reprint Farnesyl transferase inhibitors for patients with lung cancer
    Bruce E Johnson
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:4254s-4257s. 2004
  5. ncbi request reprint Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 11:5022s-5026s. 2005
  6. ncbi request reprint Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:s4628-31. 2007
  7. ncbi request reprint Epidermal growth factor receptor mutations in patients with non-small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 65:7525-9. 2005
  8. ncbi request reprint Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:4436s-4440s. 2006
  9. ncbi request reprint MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Science 316:1039-43. 2007
  10. ncbi request reprint Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma
    Toru Mukohara
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncology 68:500-10. 2005

Detail Information

Publications99

  1. ncbi request reprint Phase II study of imatinib in patients with small cell lung cancer
    Bruce E Johnson
    Dana Farber Cancer Institute, Brigham and Women s Hospital and Massachusetts General Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:5880-7. 2003
    ..The purpose of our study was to assess the objective response to imatinib administered to patients with small cell lung cancer (SCLC)...
  2. ncbi request reprint Management of small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Chest Med 23:225-39. 2002
    ..The patients who are followed in complete remission should be observed carefully for second cancers, and appropriate therapy should be administered if the cancer reappears...
  3. ncbi request reprint Basic treatment considerations using chemotherapy for patients with small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 18:309-22. 2004
  4. ncbi request reprint Farnesyl transferase inhibitors for patients with lung cancer
    Bruce E Johnson
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:4254s-4257s. 2004
    ..R115777 and L-778,123 were well tolerated in these studies but showed no significant activity as single-agent therapy in relapsed SCLC or untreated NSLC...
  5. ncbi request reprint Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 11:5022s-5026s. 2005
    ..Further research will be needed to define the role of adjuvant chemotherapy and its use in conjunction with chest radiotherapy for the treatment of patients with resected stages IA and IIIA NSCLC...
  6. ncbi request reprint Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:s4628-31. 2007
    ..A trial combining erlotinib with everolimus has been undertaken for patients with relapsed NSCLC...
  7. ncbi request reprint Epidermal growth factor receptor mutations in patients with non-small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 65:7525-9. 2005
    ....
  8. ncbi request reprint Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer
    Bruce E Johnson
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:4436s-4440s. 2006
    ..Preclinical xenograft studies have shown efficacy of pertuzumab in treating NSCLC. Therefore, a trial was undertaken for patients with relapsed NSCLC...
  9. ncbi request reprint MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Science 316:1039-43. 2007
    ..Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well...
  10. ncbi request reprint Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma
    Toru Mukohara
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncology 68:500-10. 2005
    ..Furthermore, combinations of growth factor and signal transduction inhibitors may be needed to inhibit the growth of the majority of MPM cell lines, and therefore patients with MPM...
  11. pmc Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    J Clin Invest 116:2695-706. 2006
    ....
  12. ncbi request reprint Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
    Toru Mukohara
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 97:1185-94. 2005
    ..However, little is known about the efficacy of cetuximab, an antibody against the EGFR extracellular domain, in EGFR mutant NSCLC...
  13. ncbi request reprint Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    David M Jackman
    Lowe Center of Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:3908-14. 2006
    ..Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib...
  14. pmc Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
    George N Naumov
    Children s Hospital, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, and Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Clin Cancer Res 15:3484-94. 2009
    ..EGFR TKI resistance is not completely understood and has been associated with certain EGFR and K-RAS mutations and MET amplification...
  15. pmc The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations
    Stephanie Heon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 18:4406-14. 2012
    ....
  16. doi request reprint A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma
    Lambros Zellos
    Division of Thoracic Surgery and Department of Pathology, Brigham and Women s Hospital, Boston, Mass, USA
    J Thorac Cardiovasc Surg 137:453-8. 2009
    ..This study was undertaken to determine maximum tolerated dose and toxicity of intraoperative intracavitary hyperthermic cisplatin perfusion with amifostine after extrapleural pneumonectomy for malignant pleural mesothelioma...
  17. pmc Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression
    Mizuki Nishino
    Department of Radiology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts
    Cancer 119:3761-8. 2013
    ....
  18. doi request reprint First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, 32 Fruit St, Yawkey Suite 7B, Boston, MA 02114, USA
    J Clin Oncol 26:2442-9. 2008
    ..The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms...
  19. pmc Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, Boston, MA 02114, USA
    Risk Anal 32:S117-24. 2012
    ..0% (42.0% in men, 33.3% in women). The adoption of annual screening would have prevented less than half as many lung cancer deaths as the elimination of cigarette smoking...
  20. ncbi request reprint Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells
    Takashi Kijima
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:6304-11. 2002
    ..Inhibition of both the CXCR4 and the c-Kit downstream events could be a promising therapeutic approach in SCLC...
  21. pmc New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy
    Mizuki Nishino
    Department of Radiology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02116, USA
    AJR Am J Roentgenol 195:W221-8. 2010
    ..1) to the original guidelines (RECIST 1.0) for advanced non-small cell lung cancer (NSCLC) after erlotinib therapy and to evaluate the impact of the new CT tumor measurement guideline on response assessment...
  22. pmc RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0
    Mizuki Nishino
    Department of Imaging Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston MA 02215, USA
    AJR Am J Roentgenol 201:W64-71. 2013
    ..The impact of RECIST 1.1 was compared with RECIST 1.0 in non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors...
  23. ncbi request reprint Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255
    Sean Tracy
    Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 64:7241-4. 2004
    ..These findings further characterize a mechanism by which gefitinib treatment of NSCLC harboring EGFR(L858R) leads to a dramatic response to gefitinib...
  24. pmc Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma
    Justine A Barletta
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Cell Mol Med 13:1977-86. 2009
    ..Patients with no TTF-1 expression or TTF-1 expression and TTF-1 gene amplification tend to have a significantly worse prognosis than patients with TTF-1 expression and no TTF-1 gene amplification...
  25. ncbi request reprint Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Harvard Medical School Partners Healthcare Center for Genetics and Genomics, MGH Department of Pathology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
    Oncologist 12:90-8. 2007
    ..6 years in mutation-negative patients, after adjusting for age, gender, and stage at diagnosis. Integrating molecular profiling into clinical care is feasible in NSCLC patients and provides useful clinical information...
  26. pmc Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers
    Kimio Yonesaka
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:6963-73. 2008
    ..The determinant(s) of efficacy of EGFR-targeted therapies in EGFR wild-type cancers is not well defined...
  27. ncbi request reprint c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions
    Patrick C Ma
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 63:6272-81. 2003
    ..It would now be useful to study the inhibition of c-MET as a therapeutic target against SCLC...
  28. ncbi request reprint Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
    David M Jackman
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:760-6. 2007
    ..The secondary end points include radiographic response rate, time to progression (TTP), toxicity, and symptom improvement...
  29. doi request reprint Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
    David M Jackman
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 113:808-14. 2008
    ..These agents have activity in non-small cell lung cancer, but their role in mesothelioma is unclear. The primary endpoint is response rate. Secondary endpoints include time to progression, survival, and toxicity...
  30. pmc Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung
    Andrew M Brunner
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women s Hospital, Boston, Massachusetts and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    J Thorac Oncol 8:1434-7. 2013
    ..An open-label phase II trial with dasatinib was carried out to determine the response rates in patients with SqCC who had previously failed standard chemotherapy and to correlate responses with patient genotype...
  31. ncbi request reprint Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44 Binney Street, D1234, Boston, MA 02115, USA
    Lung Cancer 44:221-30. 2004
    ....
  32. pmc Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials
    David M Jackman
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:5267-73. 2009
    ....
  33. pmc Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Lung Cancer 79:283-8. 2013
    ..TKIs are often continued beyond progressive disease by RECIST. We investigated the practice of continuing EGFR-TKIs after RECIST-PD via CT findings...
  34. ncbi request reprint Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    David M Jackman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:4517-20. 2006
  35. ncbi request reprint Inhibition of the met receptor in mesothelioma
    Toru Mukohara
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:8122-30. 2005
    ..HGF stimulation has been shown to enhance MPM cell proliferation, migration, cell scattering, and invasiveness...
  36. doi request reprint Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery
    Hale B Caglar
    Department of Radiation Oncology Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Cancer 115:4156-66. 2009
    ..The objective of this study was to identify the factors associated with improved outcome after treatment for stage III nonsmall cell lung cancer (NSCLC)...
  37. pmc Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib
    Stephanie Heon
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 16:5873-82. 2010
    ..However, there are incomplete data about their impact on the development and control of CNS metastases...
  38. ncbi request reprint EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
    ..These results suggest that EGFR mutations may predict sensitivity to gefitinib...
  39. pmc Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
    Geoffrey R Oxnard
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    J Thorac Oncol 8:179-84. 2013
    ..Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies...
  40. pmc Cost-effectiveness of computed tomography screening for lung cancer in the United States
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Thorac Oncol 6:1841-8. 2011
    ..Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level...
  41. ncbi request reprint A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:751-8. 2006
    ..Here we describe the use of a sensitive screening method that overcomes many of these limitations...
  42. pmc ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
    Jeffrey A Engelman
    Department of Systems Biology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 102:3788-93. 2005
    ..We conclude that ErbB-3 is used to couple EGFR to the PI3K/Akt pathway in gefitinib-sensitive NSCLC cell lines harboring WT and mutant EGFRs...
  43. pmc A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry
    Mari Mino-Kenudson
    Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
    Clin Cancer Res 16:1561-71. 2010
    ..In the present study, we used novel antibodies to compare ALK protein expression in genetically defined lung cancers and anaplastic large cell lymphomas...
  44. pmc Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Thorac Oncol 8:1059-68. 2013
    ....
  45. pmc Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer
    Stephanie Cardarella
    Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 19:4532-40. 2013
    ..BRAF mutations are found in a subset of non-small cell lung cancers (NSCLC). We examined the clinical characteristics and treatment outcomes of patients with NSCLC harboring BRAF mutations...
  46. doi request reprint Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer
    Junya Zhu
    Center for Patient Safety, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 119:2048-60. 2013
    ..Their relative effectiveness and comparability based on squamous versus nonsquamous histology is uncertain...
  47. pmc The introduction of systematic genomic testing for patients with non-small-cell lung cancer
    Stephanie Cardarella
    Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Thorac Oncol 7:1767-74. 2012
    ..We report the implementation of systematic prospective genotyping for somatic alterations in BRAF, PIK3CA, HER2, and ALK, in addition to EGFR and KRAS, in NSCLC patients at the Dana-Farber Cancer Institute...
  48. ncbi request reprint EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
    N Engl J Med 352:786-92. 2005
    ..Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance...
  49. ncbi request reprint LKB1 modulates lung cancer differentiation and metastasis
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 448:807-10. 2007
    ..These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis...
  50. doi request reprint Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer
    Panos Fidias
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Thorac Oncol 4:1156-62. 2009
    ....
  51. ncbi request reprint Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    John R Goffin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:3417-24. 2005
    ..A phase I study was initiated to determine whether conventional doses of carboplatin and paclitaxel are tolerated when combined with marimastat and to assess the influence of marimastat on paclitaxel pharmacokinetics...
  52. ncbi request reprint Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 62:5242-7. 2002
    ..Our findings demonstrate that in vitro, ZD1839 is as effective or more effective against MPM cell lines as it is against the NSCLC cell line A549 and suggest that ZD1839 may be an effective therapeutic option for patients with MPM...
  53. pmc The impact of genomic changes on treatment of lung cancer
    Stephanie Cardarella
    1 Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts and
    Am J Respir Crit Care Med 188:770-5. 2013
    ....
  54. ncbi request reprint Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 67:4933-9. 2007
    ..These results unveil a potential common vulnerability of BRAF and KRas mutant lung tumors that potentially affects rational deployment of MEK targeted therapies to non-small-cell lung cancer patients...
  55. doi request reprint Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer
    John V Heymach
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5407-15. 2008
    ..The antitumor activity of vandetanib monotherapy or vandetanib with paclitaxel and carboplatin (VPC) was compared with paclitaxel and carboplatin (PC) in previously untreated patients with non-small-cell lung cancer (NSCLC)...
  56. ncbi request reprint The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Cell 9:485-95. 2006
    ..These data suggest that persistent EGFR signaling is required for tumor maintenance in human lung adenocarcinomas expressing EGFR mutants...
  57. ncbi request reprint Epidermal growth factor receptor mutation testing in the care of lung cancer patients
    Lecia V Sequist
    Cancer Center and Department of Medicine, Massachusetts General Hospital, and Laboratory for Molecular Medicine, Harvard Medical School, Boston 02114, USA
    Clin Cancer Res 12:4403s-4408s. 2006
    ..It is likely that mutation testing and other molecular analyses will be most useful in these two clinical situations...
  58. pmc Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization
    Jeonghee Cho
    Authors Affiliations Departments of Medical Oncology and Cancer Biology Center for Cancer Genome Discovery, Lowe Center for Thoracic Oncology, and Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute Departments of Medicine, Brigham and Women s Hospital Departments of Biological Chemistry and Molecular Pharmacology and Pathology, Harvard Medical School, Boston, Massachusetts Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea and The Broad Institute of Harvard and MIT, Cambridge, Massachusetts
    Cancer Res 73:6770-9. 2013
    ..These data imply that different EGFR mutants show differential requirements for dimerization and that disruption of dimerization may be among the antitumor mechanisms of cetuximab...
  59. pmc Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer
    Mary E Cooley
    Dana Farber Cancer Institute, Boston, MA 02115, USA mary
    Lung Cancer 76:144-9. 2012
    ..The purpose of this study was to identify determinants of smoking outcomes among cancer patients...
  60. pmc Characterizing the cancer genome in lung adenocarcinoma
    Barbara A Weir
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 450:893-8. 2007
    ..More generally, our results indicate that many of the genes that are involved in lung adenocarcinoma remain to be discovered...
  61. doi request reprint Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study
    Tamara R Tilleman
    Department of Thoracic Surgery, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Thorac Cardiovasc Surg 138:405-11. 2009
    ..We sought to prospectively determine the feasibility and safety of hyperthermic intraoperative intracavitary cisplatin perfusion immediately after extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma...
  62. ncbi request reprint Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer
    John V Heymach
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 25:4270-7. 2007
    ..The activity of vandetanib plus docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC)...
  63. ncbi request reprint Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study
    Lori J Wirth
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:1698-704. 2003
    ..To determine the maximum-tolerated dose of docetaxel (DOC) in combination with carboplatin (CAR) and thoracic radiotherapy (RT), in the setting of trimodality treatment of patients with stage III non-small cell lung cancer (NSCLC)...
  64. pmc Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Lung Cancer 78:161-6. 2012
    ..Compare the clinical characteristics, rate of recurrent venous thromboembolism (VTE) and outcome of suspected and unsuspected pulmonary embolism (PE) detected on computed tomography in patients with lung cancer...
  65. doi request reprint Adjuvant chemotherapy for surgically resected non-small cell lung cancer
    Stephanie Heon
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Dana Building 1234, Boston, MA 02215, USA
    J Thorac Cardiovasc Surg 144:S39-42. 2012
    ..Current trials are also underway to define the role of novel targeted therapies, such as inhibitors of the epidermal growth factor receptor and monoclonal antibodies, in adjuvant treatment strategies...
  66. ncbi request reprint Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy
    Lori J Wirth
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Lung Cancer 44:213-20. 2004
    ..To determine the outcome of patients with pulmonary typical and atypical carcinoid tumors treated with chemotherapy with or without radiotherapy...
  67. ncbi request reprint Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology and Dana Farber Partners Cancer Care, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Clin Cancer Res 11:4981s-4983s. 2005
  68. ncbi request reprint Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, D1234 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:3227-34. 2005
    ..The frequency of EGFR mutations, their impact on NSCLC biology, clinical treatment, and clinical trial design, as well as methods and limitations for mutation detection, will be reviewed...
  69. pmc Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period
    Pamela M McMahon
    Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
    Cancer 113:3440-9. 2008
    ..This study estimated changes in lung cancer outcomes through 2005, had chest CT screening been introduced in 1990...
  70. pmc Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma
    Ali G Saad
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 113:2129-38. 2008
    ..The authors investigated associations between immunohistochemical markers and the development of brain metastases in patients with NSCLC...
  71. ncbi request reprint A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer
    Leena Gandhi
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer 109:924-32. 2007
    ..A Phase II study was designed to evaluate VX-710 in combination with doxorubicin and vincristine in patients with sensitive, recurrent small cell lung cancer (SCLC)...
  72. ncbi request reprint High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines
    Pasi A Janne
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncogene 23:2716-26. 2004
    ..Using this array, we identified small regions of LOH that were not detected by lower density SNP arrays or by standard microsatellite marker panels...
  73. ncbi request reprint Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 95:1528-38. 2002
    ..To determine the changes in clinical trials and outcomes of patients with limited-stage small cell lung carcinoma (SCLC) treated on Phase III randomized trials initiated in North America between 1972 and 1992...
  74. pmc Imaging of lung cancer in the era of molecular medicine
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Acad Radiol 18:424-36. 2011
    ..Knowledge of the molecular basis of lung cancer is essential for radiologists to properly interpret imaging and assess response to therapy. Quantitative and functional imaging helps assessing the biologic behavior of lung cancer...
  75. pmc CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Acad Radiol 18:54-62. 2011
    ..Determine inter- and intraobserver variability of computed tomography (CT) tumor volume measurements in advanced non-small-cell lung cancer (NSCLC) patients treated in a Phase II clinical trial using chest CT...
  76. ncbi request reprint Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA
    Clin Cancer Res 13:s4583-8. 2007
    ....
  77. ncbi request reprint Novel agents in the treatment of lung cancer: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 10:4199s-4204s. 2004
  78. ncbi request reprint Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel
    Takashi Fujishita
    Lowe Center for Thoracic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncology 64:399-406. 2003
    ..Our objective of the present study was to examine the impact of prolonged exposure on the cytotoxicity of taxanes against non-small-cell lung carcinoma (NSCLC) cell lines and the clinical response and outcome of the patients...
  79. ncbi request reprint Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Pasi A Janne
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:4416s-4420s. 2006
    ..These approaches are being studied in ongoing clinical trials and will spur the development of additional technology for EGFR mutation detection...
  80. pmc Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:5216-23. 2009
    ..We evaluated the incidence and the characteristics of ALK-rearranged lung adenocarcinomas within the western population and the optimal diagnostic modality to detect ALK rearrangements in routine clinical practice...
  81. ncbi request reprint Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006
  82. ncbi request reprint Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer
    Gautam Maulik
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 8:620-7. 2002
    ..These results demonstrate that c-Met/HGF pathway is functional in SCLC, and it would be useful to target this pathway toward novel therapy...
  83. ncbi request reprint Small-cell lung cancer
    David M Jackman
    Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 366:1385-96. 2005
    ..For patients who survive long term, careful monitoring for development of a second primary tumour is necessary, with further investigation and treatment as appropriate...
  84. ncbi request reprint A metabolic study of patients with lung cancer and hyponatremia of malignancy
    John P Chute
    Department of Medicine, Duke University, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:888-96. 2006
    ..We sought to distinguish patients with hyponatremia caused by elevated AVP versus those with ectopic atrial natriuretic peptide (ANP) via this detailed metabolic study...
  85. ncbi request reprint Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA
    Radiology 248:278-87. 2008
    ....
  86. ncbi request reprint Paraneoplastic syndromes associated with small cell lung cancer
    Leena Gandhi
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Compr Canc Netw 4:631-8. 2006
    ..Both have the potential for improvement with cancer treatment...
  87. ncbi request reprint A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer
    Boris Freidlin
    Biometric Research Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 9:917-22. 2003
    ....
  88. doi request reprint Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal
    Suzanne E Dahlberg
    J Clin Oncol 26:4233-5. 2008
  89. ncbi request reprint Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma
    Marie Wislez
    Service de Pneumologie et de Reanimation Respiratoire, AP HP, Hôpital Tenon and Laboratoire de Biologie Cellulaire et d Immunopathologie Pulmonaire, Universite Paris VI, Paris, France
    J Thorac Oncol 1:S8-12. 2006
    ..The genomic changes have mostly focused on the mRNA expression arrays as well as protein studies. The current state of knowledge was reviewed, the missing information was acknowledged, and proposals for future research were identified...
  90. ncbi request reprint TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 23:5892-9. 2005
    ..Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC...
  91. doi request reprint Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting
    David A Eberhard
    Department of Pathology, Genentech Inc, San Francisco, CA, USA
    J Clin Oncol 26:983-94. 2008
    ..Recommendations for the standardization of molecular assays are also discussed...
  92. ncbi request reprint Imatinib for small cell lung cancer, aiming for a target in vivo
    Bruce E Johnson
    Clin Cancer Res 10:3235-6. 2004
  93. ncbi request reprint Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
    ..Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC)...
  94. ncbi request reprint Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer
    Melissa Means-Markwell
    Department of Medicine and Pathology, National Naval Medical Center, Bethesda, Maryland, USA
    Clin Cancer Res 9:5915-21. 2003
    ..We conducted our study to compare the number of preneoplastic lesions in the airways and nodules in the pulmonary parenchyma of patients with resected non-small cell lung cancer with the patients whose treatment included chest radiotherapy...
  95. ncbi request reprint Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning
    Bruce E Johnson
    J Natl Cancer Inst 95:1422-4. 2003
  96. ncbi request reprint Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?
    Bruce E Johnson
    J Clin Oncol 23:6813-6. 2005
  97. ncbi request reprint Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    David A Eberhard
    Department of Pathology, Genentech Inc, San Francisco, CA, USA
    J Clin Oncol 23:5900-9. 2005
    ..KRAS is frequently activated in NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described...
  98. ncbi request reprint Imatinib in small cell lung cancer
    Jean Charles Soria
    Division of Medicine, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Lung Cancer 41:S49-53. 2003
    ..Secondary endpoints included assessment of the safety and tolerance of Imatinib, and an analysis of KIT expression in tumor samples...
  99. ncbi request reprint Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer
    O S Breathnach
    Medicine Branch, Division of Clinical Sciences, National Cancer Institute NCI National Naval Medical Center, NNMC, Bethesda, Maryland, USA
    Am J Clin Oncol 25:269-73. 2002
    ..9%. In contrast to predictions from in vitro cytotoxicity models, the sequential use of prolonged infusional paclitaxel and bolus cisplatin followed by thoracic radiation does not appear to have a greater impact over shorter chemotherapy..